News coverage about X T L Biopharmaceuticals (NASDAQ:XTLB) has trended somewhat positive on Sunday, Accern reports. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. X T L Biopharmaceuticals earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 52.7099971534192 out of 100, indicating that recent press coverage is somewhat likely to have an effect on the stock’s share price in the next several days.
X T L Biopharmaceuticals (NASDAQ:XTLB) opened at $2.55 on Friday. X T L Biopharmaceuticals has a one year low of $1.93 and a one year high of $4.70.
COPYRIGHT VIOLATION WARNING: “X T L Biopharmaceuticals (XTLB) Earning Somewhat Favorable Media Coverage, Analysis Shows” was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2018/01/14/x-t-l-biopharmaceuticals-xtlb-earns-media-impact-rating-of-0-17-updated-updated.html.
X T L Biopharmaceuticals Company Profile
XTL Biopharmaceuticals Ltd. is a biopharmaceutical company. The Company focuses on the acquisition and development of pharmaceutical drugs for the treatment of medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE).
Receive News & Ratings for X T L Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X T L Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.